Topical Formulation of Repurposed FDA-Approved Compounds Inhibits Pseudomonas aeruginosa ExoU and Improves Corneal Infection Outcomes
Daniel M. Foulkes, David Garth Fernig, Keri McLean, Marie Held, John A. Harris, Yan Sun, Joanne L. Fothergill, Valerie Price, Dominic P. Byrne, Gabriela Czanner, Connie K. P. Tam, Stephen B. Kaye
This study identifies FDA-approved compounds that inhibit ExoU, a virulence factor in Pseudomonas aeruginosa, and shows their efficacy in reducing corneal infection severity in multiple models.
PLoS Pathogens · Aug 3, 2026Peer-reviewedMicrobiology